CG121 Lung cancer: costing report
A costing report and costing template have been produced by NICE to provide an implementation tool to estimate the financial impact to the NHS of implementing the CG121 Lung cancer (update)
This costing report focuses on the financial impact of the recommendations that require most change in resources to implement in England. The report has been prepared in consultation with the guideline development group, and other clinicians working in this area and has been approved for publication by the Institute. It should be noted that the cost and activity assessments in the report are estimates based on a number of assumptions. These assessments provide an indication of the likely impact of the principal recommendations and are not absolute figures.
As part of this work, a costing template has been developed to provide health communities with the ability to assess the likely local impact of the principal recommendations in the clinical guidance based on local population. Other assumptions can be altered to better reflect local circumstances.
This resource is an implementation tool and should be used alongside the published guidance. The information does not supersede or replace the guidance itself.
The Institute would welcome feedback from users to inform the development of future templates. Please email your comments to email@example.com
This page was last updated: 24 January 2012